TY - JOUR
T1 - COVID-19 and patients with cancer
T2 - Experiment of a French comprehensive cancer center
AU - Frelaut, Maxime
AU - Vaflard, Pauline
AU - Vuagnat, Perrine
AU - Bozec, Laurence
AU - Moreau, Pauline
AU - Kriegel, Irène
AU - Vanjak, Dominique
AU - Brisse, Hervé
AU - Bouleuc, Carole
AU - Cottu, Paul
N1 - Publisher Copyright:
© 2021 Société Française du Cancer
PY - 2021/6/1
Y1 - 2021/6/1
N2 - The emergence of the Coronavirus Disease 2019 (COVID-19) has caused profound upset in health systems around the world. As cancer patients seem to be at greater risk, the organization of oncological care had to be adapted. We first report the progress of the “first wave” of COVID-19 at the Institut Curie, a French comprehensive cancer center, by describing the measures implemented to limit the risk of transmission of COVID-19 while ensuring as much as possible the continuation of anticancer treatments. Then, we present the results of a prospective institutional database in which the characteristics and outcome of our patients with cancer and suffering from COVID-19 were collected. From March 13 to April 25, 2020, 141 patients followed at Institut Curie for cancer developed COVID-19, of which 26 (18%) died from it. The minimum incidence of COVID-19 in Institut Curie is estimated at 1.4% over this period. No risk factors for developing a severe form of COVID-19 related to cancer have been identified. Cancer patients do not appear to be at greater risk of developing COVID-19, nor of having a more severe form than the general population. With the current increase of COVID-19 cases, it seems essential to share the experience already acquired to minimize the impact of this crisis on the long-term outcome of patients followed for cancer.
AB - The emergence of the Coronavirus Disease 2019 (COVID-19) has caused profound upset in health systems around the world. As cancer patients seem to be at greater risk, the organization of oncological care had to be adapted. We first report the progress of the “first wave” of COVID-19 at the Institut Curie, a French comprehensive cancer center, by describing the measures implemented to limit the risk of transmission of COVID-19 while ensuring as much as possible the continuation of anticancer treatments. Then, we present the results of a prospective institutional database in which the characteristics and outcome of our patients with cancer and suffering from COVID-19 were collected. From March 13 to April 25, 2020, 141 patients followed at Institut Curie for cancer developed COVID-19, of which 26 (18%) died from it. The minimum incidence of COVID-19 in Institut Curie is estimated at 1.4% over this period. No risk factors for developing a severe form of COVID-19 related to cancer have been identified. Cancer patients do not appear to be at greater risk of developing COVID-19, nor of having a more severe form than the general population. With the current increase of COVID-19 cases, it seems essential to share the experience already acquired to minimize the impact of this crisis on the long-term outcome of patients followed for cancer.
KW - Cancer
KW - COVID-19
KW - Health-care organization
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85107905641&partnerID=8YFLogxK
U2 - 10.1016/j.bulcan.2021.02.008
DO - 10.1016/j.bulcan.2021.02.008
M3 - Article
C2 - 33896587
AN - SCOPUS:85107905641
SN - 0007-4551
VL - 108
SP - 571
EP - 580
JO - Bulletin du Cancer
JF - Bulletin du Cancer
IS - 6
ER -